Table 1.
Association of ALDH1 expression with clinical and pathologic factors in breast cancer tissues (χ2 test)
| n |
ALDH1A1 expression |
P value | ||||
|---|---|---|---|---|---|---|
| – | + | ++ | +++ | |||
| Age (years) |
147 |
52.2 ± 11.9 |
51.6 ± 13.0 |
53.2 ± 13.0 |
48.5 ± 12.7 |
0.682 |
| Tumor size (cm) |
147 |
3.9 ± 0.6 |
2.6 ± 0.2 |
2.9 ± 0.6 |
3.9 ± 0.5 |
0.103 |
| Lymph node involvement |
115 |
45 (39.1%) |
45 (39.1%) |
9 (4.0%) |
16 (13.9%) |
0.389 |
| TNM stages |
|
|
|
|
|
|
| I |
14 |
4 (28.6%) |
8 (57.1%) |
1 (7.1%) |
1 (7.1%) |
0.177 |
| II |
56 |
19 (33.9%) |
25 (44.6%) |
6 (10.7%) |
6 (10.7%) |
|
| III |
76 |
31 (40.8%) |
29 (38.2%) |
5 (6.6%) |
11 (14.5%) |
|
| IV |
1 |
0 (0.0%) |
0 (0.0%) |
0 (0.0%) |
1 (100.0%) |
|
| NOTCH1 expression |
|
|
|
|
|
|
| – |
9 |
7 (77.8%) |
2 (22.2%) |
0 (0.0%) |
0 (0.0%) |
0.044 |
| + |
26 |
7 (26.9%) |
17 (65.4%) |
2 (7.7%) |
0 (0.0%) |
|
| ++ |
24 |
10 (41.7%) |
8 (33.3%) |
1 (4.2%) |
5 (20.8%) |
|
| +++ |
88 |
30 (34.1%) |
36 (40.9%) |
8 (9.1%) |
14 (15.9%) |
|
| Ki67 expression |
|
|
|
|
|
|
| – |
79 |
38 (48.1%) |
35 (44.3%) |
6 (7.6%) |
0 (0.0%) |
0.001 |
| + |
68 |
16 (23.5%) |
28 (41.2%) |
5 (7.4%) |
19 (27.9%) |
|
| P53 expression |
|
|
|
|
|
|
| – |
100 |
35 (35.0%) |
45 (45.0%) |
8 (8.0%) |
12 (12.0%) |
0.823 |
| + |
47 |
19 (40.4%) |
18 (38.3%) |
3 (6.4%) |
7 (14.9%) |
|
| ER expression |
|
|
|
|
|
|
| – |
90 |
34 (37.8%) |
35 (38.9%) |
6 (6.7%) |
15 (16.7%) |
0.303 |
| + |
57 |
20 (35.1%) |
28 (47.4%) |
5 (8.8%) |
4 (7.0%) |
|
| PR expression |
|
|
|
|
|
|
| – |
83 |
27 (32.5%) |
38 (45.8%) |
5 (6.0%) |
13 (15.7%) |
0.400 |
| + |
64 |
27 (42.2%) |
25 (39.1%) |
6 (9.4%) |
6 (9.4%) |
|
| HER2 expression |
|
|
|
|
|
|
| – |
77 |
32 (41.6%) |
32 (41.6%) |
4 (5.2%) |
9 (11.7%) |
0.492 |
| + |
70 |
22 (31.4%) |
31 (44.3%) |
7 (10.0%) |
10 (14.3%) |
|
| Triple negativity features* |
|
|
|
|
||
| – |
108 |
40 (37.0%) |
44 (40.7%) |
10 (9.3%) |
14 (13.0%) |
0.541 |
| + |
39 |
14 (35.9%) |
19 (48.7%) |
1 (2.6%) |
5 (12.8%) |
|
| Local recurrence |
|
|
|
|
||
| Present |
40 |
8 (20.0%) |
20 (50.0%) |
6 (15.0%) |
6 (15.0%) |
0.027 |
| Absent |
107 |
46 (43.0%) |
43(40.2%) |
5 (4.7%) |
13 (12.1%) |
|
| Distant metastasis |
|
|
|
|
||
| Present |
51 |
21 (41.1%) |
20 (39.2%) |
3 (5.9%) |
7 (13.7%) |
0.809 |
| Absent | 96 | 33 (34.3%) | 43 (44.8%) | 8 (8.3%) | 12 (12.5%) | |
ALDH aldehyde dehydrogenase, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2.
* Immunohistochemically negative for ER, PR, and HER2.